glp-1 news today october 20 2025 weight loss drugs leave users low on key nutrients, study finds glp-1 news today october 20

DOI: 10.1016/j.clnu.2022.10.015

Describe how these medications compare to other weight loss interventions and how previous clinical concepts are still applicable to patient populations struggling with overweight and obesity

7.2 Relaxin-3 and the behavioral dimension of metabolic disease Relaxin-3, a member of the relaxin peptide family predominantly expressed in the nucleus incertus, signals through the RXFP3 receptor and exerts pronounced effects on feeding behavior, arousal, stress responsiveness, and cognitive processing in animal models (Smith et al., 2014)

Glyburide crosses the placenta in vivo in pregnant rats